Propofol-based total intravenous anesthesia is associated with better survival than desflurane anesthesia in glioblastoma surgery.
Anesthesia, Inhalation
/ mortality
Anesthesia, Intravenous
/ mortality
Anesthetics, Inhalation
/ administration & dosage
Anesthetics, Intravenous
/ administration & dosage
Case-Control Studies
Desflurane
/ administration & dosage
Female
Follow-Up Studies
Glioblastoma
/ mortality
Humans
Male
Middle Aged
Neurosurgical Procedures
/ mortality
Prognosis
Propofol
/ administration & dosage
Retrospective Studies
Survival Rate
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
03
2021
accepted:
19
07
2021
entrez:
5
8
2021
pubmed:
6
8
2021
medline:
30
11
2021
Statut:
epublish
Résumé
Previous research has shown that anesthetic techniques can influence patient outcomes following cancer surgery. However, the effects of anesthesia in patients undergoing glioblastoma surgery are still not known. We studied the relationship between the type of anesthesia and patient outcomes following elective glioblastoma surgery. This was a retrospective cohort study of patients who underwent elective glioblastoma surgery between January 2008 and December 2018. Patients were grouped according to the anesthesia they received, desflurane or propofol. A Kaplan-Meier analysis was conducted, and survival curves were presented from the date of surgery to death. Univariable and multivariable Cox regression models were used to compare hazard ratios for death after propensity matching. A total of 50 patients (45 deaths, 90.0%) under desflurane anesthesia and 53 patients (38 deaths, 72.0%) under propofol anesthesia were included. Thirty-eight patients remained in each group after propensity matching. Propofol anesthesia was associated with improved survival (hazard ratio, 0.51; 95% confidence interval, 0.30-0.85; P = 0.011) in a matched analysis. Furthermore, patients under propofol anesthesia exhibited less postoperative recurrence than those under desflurane anesthesia (hazard ratio, 0.60; 95% confidence interval, 0.37-0.98; P = 0.040) in a matched analysis. In this limited sample size, we observed that propofol anesthesia was associated with improved survival and less postoperative recurrence in glioblastoma surgery than desflurane anesthesia. Further investigations are needed to examine the influence of propofol anesthesia on patient outcomes following glioblastoma surgery.
Sections du résumé
BACKGROUND
Previous research has shown that anesthetic techniques can influence patient outcomes following cancer surgery. However, the effects of anesthesia in patients undergoing glioblastoma surgery are still not known. We studied the relationship between the type of anesthesia and patient outcomes following elective glioblastoma surgery.
METHODS
This was a retrospective cohort study of patients who underwent elective glioblastoma surgery between January 2008 and December 2018. Patients were grouped according to the anesthesia they received, desflurane or propofol. A Kaplan-Meier analysis was conducted, and survival curves were presented from the date of surgery to death. Univariable and multivariable Cox regression models were used to compare hazard ratios for death after propensity matching.
RESULTS
A total of 50 patients (45 deaths, 90.0%) under desflurane anesthesia and 53 patients (38 deaths, 72.0%) under propofol anesthesia were included. Thirty-eight patients remained in each group after propensity matching. Propofol anesthesia was associated with improved survival (hazard ratio, 0.51; 95% confidence interval, 0.30-0.85; P = 0.011) in a matched analysis. Furthermore, patients under propofol anesthesia exhibited less postoperative recurrence than those under desflurane anesthesia (hazard ratio, 0.60; 95% confidence interval, 0.37-0.98; P = 0.040) in a matched analysis.
CONCLUSIONS
In this limited sample size, we observed that propofol anesthesia was associated with improved survival and less postoperative recurrence in glioblastoma surgery than desflurane anesthesia. Further investigations are needed to examine the influence of propofol anesthesia on patient outcomes following glioblastoma surgery.
Identifiants
pubmed: 34351978
doi: 10.1371/journal.pone.0255627
pii: PONE-D-21-07596
pmc: PMC8341516
doi:
Substances chimiques
Anesthetics, Inhalation
0
Anesthetics, Intravenous
0
Desflurane
CRS35BZ94Q
Propofol
YI7VU623SF
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0255627Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Neurosurg Anesthesiol. 2020 Jul;32(3):227-233
pubmed: 30807485
Anaesthesia. 2004 Oct;59(10):954-9
pubmed: 15488052
Sci Rep. 2020 Mar 27;10(1):5556
pubmed: 32221316
J Clin Invest. 1981 Sep;68(3):678-85
pubmed: 7276167
Neuroreport. 2018 Dec 12;29(18):1578-1585
pubmed: 30371540
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3306-3314
pubmed: 31385537
Acta Neurochir Suppl. 2002;81:89-91
pubmed: 12168367
Anesth Analg. 2003 Nov;97(5):1331-9
pubmed: 14570648
Anesth Analg. 1997 Dec;85(6):1394-8
pubmed: 9390615
Mol Med Rep. 2015 Oct;12(4):4815-20
pubmed: 26133092
Curr Med Chem. 2017;24(27):3002-3009
pubmed: 28521700
Medicine (Baltimore). 2019 Dec;98(51):e18472
pubmed: 31861027
Oncol Lett. 2018 Jul;16(1):402-408
pubmed: 29928428
Br J Cancer. 2014 Sep 23;111(7):1338-49
pubmed: 25072260
World Neurosurg. 2011 Dec;76(6):572-9
pubmed: 22251506
Curr Pharm Des. 2019;25(28):3028-3033
pubmed: 31298158
J Cancer Res Clin Oncol. 2015 Jun;141(6):1131-7
pubmed: 25577223
PLoS One. 2019 Nov 7;14(11):e0224728
pubmed: 31697743
Br J Anaesth. 2020 Mar;124(3):271-280
pubmed: 31902588
Ups J Med Sci. 2014 Aug;119(3):251-61
pubmed: 24857018
Am J Pathol. 2010 May;176(5):2292-301
pubmed: 20363910
Radiat Oncol. 2019 Apr 29;14(1):73
pubmed: 31036031
PLoS One. 2020 Mar 17;15(3):e0230290
pubmed: 32182262
Br J Anaesth. 2006 Sep;97(3):333-9
pubmed: 16829673
Oncol Rep. 2017 May;37(5):2611-2619
pubmed: 28426124
Anesthesiology. 2016 Jan;124(1):69-79
pubmed: 26556730
PLoS One. 2020 May 21;15(5):e0233598
pubmed: 32437450
Toxicol In Vitro. 2012 Sep;26(6):862-71
pubmed: 22579810
CNS Neurosci Ther. 2019 Jun;25(6):704-713
pubmed: 30680941
Int J Radiat Oncol Biol Phys. 1993 May 20;26(2):239-44
pubmed: 8387988
N Engl J Med. 2011 Aug 18;365(7):591-600
pubmed: 21848460
J Am Coll Cardiol. 2002 Feb 6;39(3):542-53
pubmed: 11823097
Anaesthesia. 2021 Sep;76(9):1198-1206
pubmed: 33440019
Medicine (Baltimore). 2020 Jun 19;99(25):e20714
pubmed: 32569207
Anesthesiology. 2018 Nov;129(5):932-941
pubmed: 30028726
Anesthesiology. 2013 Sep;119(3):593-605
pubmed: 23774231
Br J Anaesth. 2019 Aug;123(2):151-160
pubmed: 31171343
Lancet. 2019 Nov 16;394(10211):1807-1815
pubmed: 31645288
Immunopharmacol Immunotoxicol. 2007;29(3-4):477-86
pubmed: 18075859
J Cancer. 2019 May 26;10(11):2397-2406
pubmed: 31258744
Cancer Lett. 2002 Oct 28;184(2):165-70
pubmed: 12127688
Am J Clin Oncol. 2018 Feb;41(2):191-196
pubmed: 28832384
Br J Anaesth. 2010 Aug;105(2):106-15
pubmed: 20627881
Can J Anaesth. 1997 Jan;44(1):90-4
pubmed: 8988831
Neurosurg Rev. 2020 Dec 22;:
pubmed: 33354749
World Neurosurg. 2018 Jun;114:e254-e266
pubmed: 29524715
Oncogene. 2016 Nov 10;35(45):5819-5825
pubmed: 27041580
Anesthesiology. 2005 Jun;102(6):1147-57
pubmed: 15915027
Acta Pharmacol Sin. 2019 Nov;40(11):1424-1435
pubmed: 30967592
Can J Anaesth. 2009 Mar;56(3):222-9
pubmed: 19247743
Environ Toxicol. 2017 Dec;32(12):2440-2454
pubmed: 28804952